Masayuki Yazawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masayuki Yazawa has a total of 145 co-authors. Here are the top co-authors by number of shared publications:
Fuun Kawano
Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA
5 shared publicationsAlison D. Klein
Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA
4 shared publicationsKumi Morikawa
Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA
4 shared publicationsRamsey Bekdash
Affiliations Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, New York, United States of America, Columbia Stem Cell Initiative, Columbia University, New York, New York, United States of America, Department of Pharmacology, Columbia University, New York, New York, United States of America
4 shared publicationsHannah E. Yamamoto
Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA
3 shared publicationsJose R. Quejada
Columbia Stem Cell Initiative, Department of Rehabilitation and Regenerative Medicine, Columbia University, New York, USA
3 shared publications
Latest Publications
- Open Access
- 14 March 2024
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 22 (3) , e3002522
Developing inhibitory peptides against SARS-CoV-2 envelope protein
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected approximately 800 million people since the start of the Coronavirus Disease 2019 (COVID-19) pandemic. Because of the high rate of mutagenesis in SARS-CoV-2, it is difficult to develop a sustainable approach for prevention and treatment. The Envelope (E) protein is highly conserved among human coronaviruses. Previous studies reported that SARS-CoV-1 E deficiency reduced viral propagation, suggesting that E inhibition might be an effective therapeutic strategy for SARS-CoV-2. Here, we report inhibitory peptides against SARS-CoV-2 E protein named iPep-SARS2-E. Leveraging E-induced alterations in proton homeostasis and NFAT/AP-1 pathway in mammalian cells, we developed screening platforms to design and optimize the peptides that bind and inhibit E protein. Using Vero-E6 cells, human-induced pluripotent stem cell-derived branching lung organoid and mouse models with SARS-CoV-2, we found that iPep-SARS2-E significantly inhibits virus egress and reduces viral cytotoxicity and propagation in vitro and in vivo. Furthermore, the peptide can be customizable for E protein of other human coronaviruses such as Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The results indicate that E protein can be a potential therapeutic target for human coronaviruses.
- 14 March 2024
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 22 (3) , e3002522
Open AccessDeveloping inhibitory peptides against SARS-CoV-2 envelope protein
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has affected approximately 800 million people since the start of the Coronavirus Disease 2019 (COVID-19) pandemic. Because of the high rate of mutagenesis in SARS-CoV-2, it is difficult to develop a sustainable approach for prevention and treatment. The Envelope (E) protein is highly conserved among human coronaviruses. Previous studies reported that SARS-CoV-1 E deficiency reduced viral propagation, suggesting that E inhibition might be an effective therapeutic strategy for SARS-CoV-2. Here, we report inhibitory peptides against SARS-CoV-2 E protein named iPep-SARS2-E. Leveraging E-induced alterations in proton homeostasis and NFAT/AP-1 pathway in mammalian cells, we developed screening platforms to design and optimize the peptides that bind and inhibit E protein. Using Vero-E6 cells, human-induced pluripotent stem cell-derived branching lung organoid and mouse models with SARS-CoV-2, we found that iPep-SARS2-E significantly inhibits virus egress and reduces viral cytotoxicity and propagation in vitro and in vivo. Furthermore, the peptide can be customizable for E protein of other human coronaviruses such as Middle East Respiratory Syndrome Coronavirus (MERS-CoV). The results indicate that E protein can be a potential therapeutic target for human coronaviruses.
- 13 June 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (11) , 1672-1679
A red light–responsive photoswitch for deep tissue optogenetics
Red light penetrates deep into mammalian tissues and has low phototoxicity, but few optogenetic tools that use red light have been developed. Here we present MagRed, a red light–activatable photoswitch that consists of a red light–absorbing bacterial phytochrome incorporating a mammalian endogenous chromophore, biliverdin and a photo-state-specific binder that we developed using Affibody library selection. Red light illumination triggers the binding of the two components of MagRed and the assembly of split-proteins fused to them. Using MagRed, we developed a red light–activatable Cre recombinase, which enables light-activatable DNA recombination deep in mammalian tissues. We also created red light–inducible transcriptional regulators based on CRISPR–Cas9 that enable an up to 378-fold activation (average, 135-fold induction) of multiple endogenous target genes. MagRed will facilitate optogenetic applications deep in mammalian organisms in a variety of biological research areas.
- 13 June 2022
- Published by Springer Nature in Nature Biotechnology
- Vol. 40 (11) , 1672-1679
A red light–responsive photoswitch for deep tissue optogenetics
Red light penetrates deep into mammalian tissues and has low phototoxicity, but few optogenetic tools that use red light have been developed. Here we present MagRed, a red light–activatable photoswitch that consists of a red light–absorbing bacterial phytochrome incorporating a mammalian endogenous chromophore, biliverdin and a photo-state-specific binder that we developed using Affibody library selection. Red light illumination triggers the binding of the two components of MagRed and the assembly of split-proteins fused to them. Using MagRed, we developed a red light–activatable Cre recombinase, which enables light-activatable DNA recombination deep in mammalian tissues. We also created red light–inducible transcriptional regulators based on CRISPR–Cas9 that enable an up to 378-fold activation (average, 135-fold induction) of multiple endogenous target genes. MagRed will facilitate optogenetic applications deep in mammalian organisms in a variety of biological research areas.
- 17 February 2022
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 1 (2) , 142-156
Sigma non-opioid receptor 1 is a potential therapeutic target for long QT syndrome
Some missense gain-of-function mutations in the CACNA1C gene, encoding calcium channel CaV1.2, cause a life-threatening form of long QT syndrome (LQTS) named Timothy syndrome with currently no clinically effective therapeutics. Here we report that pharmacological targeting of sigma non-opioid intracellular receptor 1 (SIGMAR1) can restore electrophysiological function in induced pluripotent stem cell (iPSC)-derived cardiomyocytes generated from patients with Timothy syndrome and two common forms of LQTS, type 1 (LQTS1) and type 2 (LQTS2), caused by missense trafficking mutations in potassium channels. Electrophysiological recordings demonstrate that a Food and Drug Administration (FDA)-approved cough suppressant, dextromethorphan, can be used as an agonist of SIGMAR1 to shorten the prolonged action potential in cardiomyocytes from patients with Timothy syndrome and human cellular models of LQTS1 and LQTS2. When tested in vivo, dextromethorphan also normalized the prolonged QT intervals in a mouse model of Timothy syndrome. Overall, our study demonstrates that SIGMAR1 is a potential therapeutic target for Timothy syndrome and possibly other inherited arrhythmias such as LQTS1 and LQTS2.
- 17 February 2022
- Published by Springer Nature in Nature Cardiovascular Research
- Vol. 1 (2) , 142-156
Sigma non-opioid receptor 1 is a potential therapeutic target for long QT syndrome
Some missense gain-of-function mutations in the CACNA1C gene, encoding calcium channel CaV1.2, cause a life-threatening form of long QT syndrome (LQTS) named Timothy syndrome with currently no clinically effective therapeutics. Here we report that pharmacological targeting of sigma non-opioid intracellular receptor 1 (SIGMAR1) can restore electrophysiological function in induced pluripotent stem cell (iPSC)-derived cardiomyocytes generated from patients with Timothy syndrome and two common forms of LQTS, type 1 (LQTS1) and type 2 (LQTS2), caused by missense trafficking mutations in potassium channels. Electrophysiological recordings demonstrate that a Food and Drug Administration (FDA)-approved cough suppressant, dextromethorphan, can be used as an agonist of SIGMAR1 to shorten the prolonged action potential in cardiomyocytes from patients with Timothy syndrome and human cellular models of LQTS1 and LQTS2. When tested in vivo, dextromethorphan also normalized the prolonged QT intervals in a mouse model of Timothy syndrome. Overall, our study demonstrates that SIGMAR1 is a potential therapeutic target for Timothy syndrome and possibly other inherited arrhythmias such as LQTS1 and LQTS2.
- Open Access
- 21 October 2021
- Published by Elsevier in Cell Reports Methods
- Vol. 1 (7) , 100092
GEM-IL: A highly responsive fluorescent lactate indicator
- 21 October 2021
- Published by Elsevier in Cell Reports Methods
- Vol. 1 (7) , 100092
Open AccessGEM-IL: A highly responsive fluorescent lactate indicator
- Open Access
- 5 May 2021
- Published by Springer Nature in Research Square
A semi-synthetic red light photoswitch for optogenetic control of protein activity
Red light is useful for optogenetic control of various protein activities in mammalian deep tissues due to its high tissue penetration, low invasiveness, and low light scattering. However, technology that enables for the optogenetic manipulation using red light remains elusive. Here we develop a red light-activatable, semi-synthetic photoswitch, named MagRed. MagRed is composed of a red light-absorbing bacterial phytochrome incorporating a mammalian endogenous chromophore, biliverdin, and its photo-state-specific de novo synthetic binder. MagRed allows us to reassemble split-proteins using red light and thereby develop a red light-activatable Cre recombinase, which is applicable for mammalian deep tissues. Additionally, we take advantage of MagRed to develop red light-inducible transcription system based on the CRISPR-Cas9 system, enabling for high induction (up to 378-fold) of multiple user-defined endogenous target genes. With high versatility and regulatability, MagRed provides a powerful technology that easily facilitates optogenetics applications for a variety of biological research areas.
- 5 May 2021
- Published by Springer Nature in Research Square
Open AccessA semi-synthetic red light photoswitch for optogenetic control of protein activity
Red light is useful for optogenetic control of various protein activities in mammalian deep tissues due to its high tissue penetration, low invasiveness, and low light scattering. However, technology that enables for the optogenetic manipulation using red light remains elusive. Here we develop a red light-activatable, semi-synthetic photoswitch, named MagRed. MagRed is composed of a red light-absorbing bacterial phytochrome incorporating a mammalian endogenous chromophore, biliverdin, and its photo-state-specific de novo synthetic binder. MagRed allows us to reassemble split-proteins using red light and thereby develop a red light-activatable Cre recombinase, which is applicable for mammalian deep tissues. Additionally, we take advantage of MagRed to develop red light-inducible transcription system based on the CRISPR-Cas9 system, enabling for high induction (up to 378-fold) of multiple user-defined endogenous target genes. With high versatility and regulatability, MagRed provides a powerful technology that easily facilitates optogenetics applications for a variety of biological research areas.
- Top Cited Papers
- 28 September 2020
- Published by Springer Nature in Nature Medicine
- Vol. 26 (12) , 1888-1898
Neuronal defects in a human cellular model of 22q11.2 deletion syndrome
22q11.2 deletion syndrome (22q11DS) is a highly penetrant and common genetic cause of neuropsychiatric disease. Here we generated induced pluripotent stem cells from 15 individuals with 22q11DS and 15 control individuals and differentiated them into three-dimensional (3D) cerebral cortical organoids. Transcriptional profiling across 100 days showed high reliability of differentiation and revealed changes in neuronal excitability-related genes. Using electrophysiology and live imaging, we identified defects in spontaneous neuronal activity and calcium signaling in both organoid- and 2D-derived cortical neurons. The calcium deficit was related to resting membrane potential changes that led to abnormal inactivation of voltage-gated calcium channels. Heterozygous loss of DGCR8 recapitulated the excitability and calcium phenotypes and its overexpression rescued these defects. Moreover, the 22q11DS calcium abnormality could also be restored by application of antipsychotics. Taken together, our study illustrates how stem cell derived models can be used to uncover and rescue cellular phenotypes associated with genetic forms of neuropsychiatric disease.
- 28 September 2020
- Published by Springer Nature in Nature Medicine
- Vol. 26 (12) , 1888-1898
Top Cited PapersNeuronal defects in a human cellular model of 22q11.2 deletion syndrome
22q11.2 deletion syndrome (22q11DS) is a highly penetrant and common genetic cause of neuropsychiatric disease. Here we generated induced pluripotent stem cells from 15 individuals with 22q11DS and 15 control individuals and differentiated them into three-dimensional (3D) cerebral cortical organoids. Transcriptional profiling across 100 days showed high reliability of differentiation and revealed changes in neuronal excitability-related genes. Using electrophysiology and live imaging, we identified defects in spontaneous neuronal activity and calcium signaling in both organoid- and 2D-derived cortical neurons. The calcium deficit was related to resting membrane potential changes that led to abnormal inactivation of voltage-gated calcium channels. Heterozygous loss of DGCR8 recapitulated the excitability and calcium phenotypes and its overexpression rescued these defects. Moreover, the 22q11DS calcium abnormality could also be restored by application of antipsychotics. Taken together, our study illustrates how stem cell derived models can be used to uncover and rescue cellular phenotypes associated with genetic forms of neuropsychiatric disease.
- 1 September 2020
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 107, 103529
Timothy syndrome iPSC modeling
- 1 September 2020
- Published by Elsevier in Molecular and Cellular Neuroscience
- Vol. 107, 103529
Timothy syndrome iPSC modeling
- Open Access
- 23 June 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (6) , e0234913
Perm1 regulates cardiac energetics as a downstream target of the histone methyltransferase Smyd1
The transcriptional regulatory machinery in mitochondrial bioenergetics is complex and is still not completely understood. We previously demonstrated that the histone methyltransferase Smyd1 regulates mitochondrial energetics. Here, we identified Perm1 (PPARGC-1 and ESRR-induced regulator, muscle specific 1) as a downstream target of Smyd1 through RNA-seq. Chromatin immunoprecipitation assay showed that Smyd1 directly interacts with the promoter of Perm1 in the mouse heart, and this interaction was significantly reduced in mouse hearts failing due to pressure overload for 4 weeks, where Perm1 was downregulated (24.4 ± 5.9% of sham, pNdufv1 (Complex I). Pathway enrichment analysis of cardiomyocytes in which Perm1 was knocked-down by siRNA (siPerm1), revealed that the most downregulated pathway was metabolism. Cell stress tests using the Seahorse XF analyzer showed that basal respiration and ATP production were significantly reduced in siPerm1 cardiomyocytes (40.7% and 23.6% of scrambled-siRNA, respectively, both pERRα gene and known target of ERRα, Ndufv1 (Complex I). Overall, our study demonstrates that Perm1 is an essential regulator of cardiac energetics through ERRα, as part of the Smyd1 regulatory network.
- 23 June 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (6) , e0234913
Open AccessPerm1 regulates cardiac energetics as a downstream target of the histone methyltransferase Smyd1
The transcriptional regulatory machinery in mitochondrial bioenergetics is complex and is still not completely understood. We previously demonstrated that the histone methyltransferase Smyd1 regulates mitochondrial energetics. Here, we identified Perm1 (PPARGC-1 and ESRR-induced regulator, muscle specific 1) as a downstream target of Smyd1 through RNA-seq. Chromatin immunoprecipitation assay showed that Smyd1 directly interacts with the promoter of Perm1 in the mouse heart, and this interaction was significantly reduced in mouse hearts failing due to pressure overload for 4 weeks, where Perm1 was downregulated (24.4 ± 5.9% of sham, pNdufv1 (Complex I). Pathway enrichment analysis of cardiomyocytes in which Perm1 was knocked-down by siRNA (siPerm1), revealed that the most downregulated pathway was metabolism. Cell stress tests using the Seahorse XF analyzer showed that basal respiration and ATP production were significantly reduced in siPerm1 cardiomyocytes (40.7% and 23.6% of scrambled-siRNA, respectively, both pERRα gene and known target of ERRα, Ndufv1 (Complex I). Overall, our study demonstrates that Perm1 is an essential regulator of cardiac energetics through ERRα, as part of the Smyd1 regulatory network.
- Open Access
- 29 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (22) , eaba6712
Sequentially addressable dielectrophoretic array for high-throughput sorting of large-volume biological compartments
Droplet microfluidics has become a powerful tool in precision medicine, green biotechnology, and cell therapy for single-cell analysis and selection by virtue of its ability to effectively confine cells. However, there remains a fundamental trade-off between droplet volume and sorting throughput, limiting the advantages of droplet microfluidics to small droplets (Saccharomyces cerevisiae based on their growth rate.
- 29 May 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (22) , eaba6712
Open AccessSequentially addressable dielectrophoretic array for high-throughput sorting of large-volume biological compartments
Droplet microfluidics has become a powerful tool in precision medicine, green biotechnology, and cell therapy for single-cell analysis and selection by virtue of its ability to effectively confine cells. However, there remains a fundamental trade-off between droplet volume and sorting throughput, limiting the advantages of droplet microfluidics to small droplets (Saccharomyces cerevisiae based on their growth rate.
- Open Access
- 1 May 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-11
Photoactivatable Cre recombinase 3.0 for in vivo mouse applications
Optogenetic genome engineering tools enable spatiotemporal control of gene expression and provide new insight into biological function. Here, we report the new version of genetically encoded photoactivatable (PA) Cre recombinase, PA-Cre 3.0. To improve PA-Cre technology, we compare light-dimerization tools and optimize for mammalian expression using a CAG promoter, Magnets, and 2A self-cleaving peptide. To prevent background recombination caused by the high sequence similarity in the dimerization domains, we modify the codons for mouse gene targeting and viral production. Overall, these modifications significantly reduce dark leak activity and improve blue-light induction developing our new version, PA-Cre 3.0. As a resource, we have generated and validated AAV-PA-Cre 3.0 as well as two mouse lines that can conditionally express PA-Cre 3.0. Together these new tools will facilitate further biological and biomedical research.
- 1 May 2020
- Published by Springer Nature in Nature Communications
- Vol. 11 (1) , 1-11
Open AccessPhotoactivatable Cre recombinase 3.0 for in vivo mouse applications
Optogenetic genome engineering tools enable spatiotemporal control of gene expression and provide new insight into biological function. Here, we report the new version of genetically encoded photoactivatable (PA) Cre recombinase, PA-Cre 3.0. To improve PA-Cre technology, we compare light-dimerization tools and optimize for mammalian expression using a CAG promoter, Magnets, and 2A self-cleaving peptide. To prevent background recombination caused by the high sequence similarity in the dimerization domains, we modify the codons for mouse gene targeting and viral production. Overall, these modifications significantly reduce dark leak activity and improve blue-light induction developing our new version, PA-Cre 3.0. As a resource, we have generated and validated AAV-PA-Cre 3.0 as well as two mouse lines that can conditionally express PA-Cre 3.0. Together these new tools will facilitate further biological and biomedical research.